Dominique, Alyssa
Hetland, Merete Lund
Finckh, Axel
Gottenberg, Jacques-Eric
Iannone, Florenzo
Caporali, Roberto
Kou, Tzuyung Douglas
Nordstrom, Dan
Hernandez, Maria Victoria
Sánchez-Piedra, Carlos
Sánchez-Alonso, Fernando
Pavelka, Karel
Bond, T. Christopher
Simon, Teresa A.
Article History
Received: 5 December 2022
Accepted: 11 May 2023
First Online: 12 June 2023
Declarations
:
: This study was conducted in accordance with the International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices, applicable regulatory requirements in each country, and the principles of the Declaration of Helsinki.
: Not applicable.
: AD: employee and shareholder: Bristol Myers Squibb (at the time of analysis); employee: Pfizer (current); MLH: grant/research support: AbbVie, Biogen, Bristol Myers Squibb, Merck, Novartis, Pfizer, Roche, Sandoz; consulting fees: Biogen, Celltrion, Eli Lilly, Merck, Orion Pharma, Pfizer, Samsung Bioepis; AF: grant/research support: AbbVie, Bristol Myers Squibb, Eli Lilly, Galapagos, Pfizer; speaker fees/honoraria: AB2Bio, AbbVie, Bristol Myers Squibb, Eli Lilly, Pfizer, Sandoz, Sanofi; J-EG: grant/research support, consulting fees: Bristol Myers Squibb, Eli Lilly, Pfizer; consulting fees: AbbVie, Bristol Myers Squibb, CSL Behring, Galapagos, Gilead, Merck Sharp & Dohme, Pfizer, Sanofi-Regeneron; FI: speaker fees/honoraria: AbbVie, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, UCB; RC: speaker fees/honoraria: AbbVie, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, UCB; TDK: employee: Bristol Myers Squibb (at the time of analysis), BeiGene USA, Inc. (current); DN: consulting fees, speaker fees/honoraria: AbbVie, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, UCB; MVH, CS-P, FS-A: nothing to disclose; KP: speaker fees/honoraria: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Egis, Merck Sharp & Dohme, Novartis, Pfizer, Roche, UCB; TCB: employee and shareholder: Bristol Myers Squibb; TAS: employee and shareholder: Bristol Myers Squibb (at the time of analysis); employee: Physicians Research Center (current); consulting fees: Bristol Myers Squibb.